HUTCHMED (HCM) said late Wednesday that China's National Medical Products Administration has granted breakthrough therapy designation to Orpathys in combination with Tagrisso to treat non-small cell lung cancer patients.
The designation qualifies the treatment candidate for a potential conditional approval and priority review, the company said.
The drug cocktail is currently being evaluated in a phase 3 trial in China.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments